Cargando…

P28 Rezafungin efficacy and safety in immunocompromised patients: sub-analyses of the Phase 3 trial in treatment of candidaemia and invasive candidiasis

BACKGROUND: Rezafungin (RZF) once weekly (QWk) is a next-generation echinocandin in development for treatment of candidaemia and invasive candidiasis (IC) and for prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis spp. in BMT. OBJECTIVES: The Phase 3 ReSTORE treat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sandison, Taylor, Ramos-Martinez, Antonio, Kim, Young Keun, Chai, Louis, Slavin, Monica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266150/ http://dx.doi.org/10.1093/jacamr/dlad066.032

Ejemplares similares

P27 Rezafungin treatment of candidaemia and invasive candidiasis: outcomes stratified by baseline renal function—analysis of the Phase 2 + Phase 3 trials
por: Sandison, Taylor, et al.
Publicado: (2023)

P29 Outcomes by baseline pathogen and susceptibility in the ReSTORE Phase 3 trial of rezafungin once weekly compared with caspofungin once daily in patients with candidaemia and/or invasive candidiasis
por: Thompson, G R, et al.
Publicado: (2023)

P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis
por: Soriano, A, et al.
Publicado: (2023)

Pharmacokinetics of micafungin in adult patients with invasive candidiasis and candidaemia
por: Kuse, ER, et al.
Publicado: (2008)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

1174. Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations
por: Flanagan, Shawn, et al.
Publicado: (2020)

1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study
por: Thompson, George R, et al.
Publicado: (2018)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Anidulafungin for the treatment of candidaemia/invasive candidiasis in selected critically ill patients
por: Ruhnke, M, et al.
Publicado: (2012)

637. Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Vazquez, Jose A, et al.
Publicado: (2020)

1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin
por: Thompson, George R, et al.
Publicado: (2020)

Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
por: Thompson, George R, et al.
Publicado: (2020)

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia
por: Miesel, Lynn, et al.
Publicado: (2021)

Cost-effectiveness analysis of anidulafungin for the treatment of candidaemia and other forms of invasive candidiasis
por: Auzinger, Georg, et al.
Publicado: (2015)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations
por: Flanagan, Shawn, et al.
Publicado: (2023)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

Metabolism, Excretion, and Mass Balance of [(14)C]-Rezafungin in Animals and Humans
por: Ong, Voon, et al.
Publicado: (2022)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

Determinants of mortality in non-neutropenic ICU patients with candidaemia
por: Marriott, Deborah JE, et al.
Publicado: (2009)

1286. Pharmacokinetics, Excretion, and Mass Balance of [(14)C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults
por: Ong, Voon, et al.
Publicado: (2020)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

Invasive candidiasis leading to gastric perforation in an immunocompromised patient
por: Karasuno, Takahiro, et al.
Publicado: (2019)

Erratum to: Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial
Publicado: (2021)

A phase I randomized, double‐blind, single subcutaneous dose escalation study to determine the safety, tolerability, and pharmacokinetics of rezafungin in healthy adult subjects
por: Gu, Kenan, et al.
Publicado: (2022)

Health-economic modelling of cost savings due to the use of rezafungin based on a German cost-of-illness study of candidiasis
por: Jeck, Julia, et al.
Publicado: (2023)

Biofilm profile of candidaemia isolates
por: Sheena, M.S., et al.
Publicado: (2023)

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
por: Hager, Christopher L, et al.
Publicado: (2018)

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2018)

A real time PCR assay on blood for diagnosis of invasive candidiasis in immunocompromised patient
por: Ashrafi, M, et al.
Publicado: (2015)

Candidaemia and cancer: patients are not all the same
por: Pasqualotto, Alessandro Comarú, et al.
Publicado: (2006)

Candidaemia in a tertiary hospital in Nigeria
por: Oladele, Rita O., et al.
Publicado: (2014)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

Mortality in patients with early- or late-onset candidaemia
por: De Rosa, Francesco Giuseppe, et al.
Publicado: (2013)

Cost-effectiveness analysis of anidulafungin in the treatment of candidaemia
por: Auzinger, G, et al.
Publicado: (2013)

Endocarditis Is Not Rare and Is an Independent Predictor of Mortality in Candidaemia
por: Aye, Chaw, et al.
Publicado: (2017)

Dexamethasone/methylprednisolone/tocilizumab: Candidaemia: case report
Publicado: (2021)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Candidaemia and a risk predictive model for overall mortality: a prospective multicentre study
por: Keighley, C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_e7f8tk3vf1rdf3r55ev5ts1c5r